Clinical trial
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk…
NCT00393783 · Memorial Sloan Kettering Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00393783 |
|---|---|
| Title | Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity |
| Official title | Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | MAB HER 2 (HERCEPTIN) |
| Enrollment | 13 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2026 |
| Completion | May 1, 2026 |
| First posted | Oct 30, 2006 |
| Last update posted | Jun 5, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: